Volume 10, Issue 1 (6-2023)                   NBR 2023, 10(1): 1-10 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Gholami L, Attari F, Talkhabi M, Saadatpour F. The effect of glycolysis inhibitor dichloroacetate on the apoptosis rate and alteration of gene and miRNA expression of breast cancer cells MDA-MB-231. NBR 2023; 10 (1) :1-10
URL: http://nbr.khu.ac.ir/article-1-3593-en.html
Department of Animal Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran , attari@ut.ac.ir
Abstract:   (1793 Views)
Breast cancer is the most common cause of death from cancer among women. The triple-negative breast cancer (TNBC) is the most invasive subtype, and chemotherapy is the only therapy option. Cancer cells preferably utilize the glycolysis pathway even with proper oxygen availability, and this activation plays a great role in tumorigenesis. Therefore, glycolysis targeting can be an effective strategy for cancer treatment. Here, the apoptotic effect of a glycolysis inhibitor named dichloroacetate (DCA) on TNBC cells MDA-MB-231 was assessed, and the expression of anti-apoptotic genes and oncogenic miRNAs was evaluated. MTT assay showed that DCA reduces cell viability in a dose-dependent manner with the IC50 concentration of 50 mM. Annexin/PI assay demonstrated that DCA due to DCA treatment. Finally, the expression of anti-apoptotic genes Bcl2l1 and Mcl1 and oncogenic miRNAs miR21 and miR27a decreased due to DCA treatment. Our results confirmed that DCA, as a glycolysis inhibitor, leads to apoptosis induction in TNBC cells because of reducing expression of viability genes and miRNAs.
Full-Text [PDF 563 kb]   (729 Downloads)    
Type of Study: Original Article | Subject: Cell and Molecular Biology
Received: 2022/12/8 | Revised: 2023/06/26 | Accepted: 2023/01/21 | Published: 2023/06/20 | ePublished: 2023/06/20

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Nova Biologica Reperta

Designed & Developed by : Yektaweb